Elizabeth H.Z. Thompson, who serves as Executive Vice President and Head of Research & Development at ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), reported the exercise of options and a related stock sale in consecutive filings with the Securities and Exchange Commission.
According to a Form 4 filing, Thompson exercised options covering 6,715 shares of Acadia common stock on March 24, 2026, at an exercise price of $0. The filing notes that those shares were connected to the vesting of restricted stock units. The next day, March 25, 2026, Thompson sold 3,435 shares of common stock at $21.47 per share, producing gross proceeds of approximately $73,749.
Following the sale, Thompson directly holds 3,280 shares of Acadia common stock, the filing shows.
Valuation context and analyst activity
InvestingPro analysis cited in the disclosure indicates that Acadia's shares appear undervalued at current levels, with a reported price-to-earnings ratio of 9.4. Separately, BofA Securities adjusted its rating on the company, moving from Neutral to Buy while retaining a price target of $29. The firm had previously trimmed that target from $31 amid a company pipeline review and complications in the European market.
Regulatory and governance developments
On the regulatory front, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on Acadia’s trofinetide for the treatment of Rett syndrome. The committee cited concerns related to the therapy’s efficacy and limitations in the underlying studies.
In governance news, Acadia announced the immediate appointment of Jonathan M. Poole to its board of directors and audit committee. The appointment was made effective immediately and was approved following a recommendation from the company’s nominating and corporate governance committee.
What the filings and announcements together show
The sequence of disclosures recorded in the Form 4 connects an option exercise tied to restricted stock unit vesting with a subsequent partial sale of shares by an executive officer. The corporate announcements captured alongside the trading activity include an analyst upgrade with an unchanged $29 price target, a negative regulatory opinion in Europe for a flagship product candidate, and a board appointment approved by the nominating and corporate governance committee.
The filings and company statements were limited to the facts presented above; they do not provide additional commentary on motives for the option exercise or sale.